Bachem Holding AG

LSE:0QND Stock Report

Market Cap: CHF 5.1b

Bachem Holding Valuation

Is 0QND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QND (CHF68.15) is trading above our estimate of fair value (CHF24.48)

Significantly Below Fair Value: 0QND is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QND?

Key metric: As 0QND is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QND. This is calculated by dividing 0QND's market cap by their current earnings.
What is 0QND's PE Ratio?
PE Ratio45.2x
EarningsCHF 113.57m
Market CapCHF 5.14b

Price to Earnings Ratio vs Peers

How does 0QND's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.7x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
9.9x-15.2%UK£172.8m
HIK Hikma Pharmaceuticals
17.8x11.2%UK£4.0b
GNS Genus
140.2x37.0%UK£1.1b
0QND Bachem Holding
45.2x17.9%CHF 5.1b

Price-To-Earnings vs Peers: 0QND is good value based on its Price-To-Earnings Ratio (45.2x) compared to the peer average (56x).

Price to Earnings Ratio vs Industry

How does 0QND's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0QND 45.2xIndustry Avg. 36.9xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QND is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the European Life Sciences industry average (36.9x).

Price to Earnings Ratio vs Fair Ratio

What is 0QND's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QND PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.2x
Fair PE Ratio27x

Price-To-Earnings vs Fair Ratio: 0QND is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the estimated Fair Price-To-Earnings Ratio (27x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 68.15
CHF 85.00
+24.7%
12.2%CHF 100.00CHF 71.00n/a7
Nov ’25CHF 69.89
CHF 84.83
+21.4%
13.2%CHF 100.00CHF 71.00n/a6
Oct ’25CHF 70.25
CHF 82.83
+17.9%
16.0%CHF 100.00CHF 65.00n/a6
Sep ’25CHF 81.33
CHF 82.83
+1.8%
16.0%CHF 100.00CHF 65.00n/a6
Aug ’25CHF 79.05
CHF 77.14
-2.4%
22.9%CHF 100.00CHF 52.00n/a7
Jul ’25CHF 83.65
CHF 75.67
-9.5%
22.1%CHF 100.00CHF 52.00n/a6
Jun ’25CHF 80.85
CHF 70.80
-12.4%
19.6%CHF 85.00CHF 52.00n/a5
May ’25CHF 80.15
CHF 70.80
-11.7%
19.6%CHF 85.00CHF 52.00n/a5
Apr ’25CHF 86.42
CHF 70.80
-18.1%
19.6%CHF 85.00CHF 52.00n/a5
Mar ’25CHF 68.70
CHF 71.17
+3.6%
17.6%CHF 85.00CHF 52.00n/a6
Feb ’25CHF 58.21
CHF 71.17
+22.3%
17.6%CHF 85.00CHF 52.00n/a6
Jan ’25CHF 65.01
CHF 73.17
+12.5%
13.7%CHF 85.00CHF 56.00n/a6
Dec ’24CHF 63.76
CHF 75.33
+18.2%
9.3%CHF 85.00CHF 64.00n/a6
Nov ’24CHF 65.30
CHF 75.33
+15.4%
9.3%CHF 85.00CHF 64.00CHF 69.896
Oct ’24CHF 68.65
CHF 77.00
+12.2%
12.7%CHF 95.00CHF 64.00CHF 70.256
Sep ’24CHF 82.05
CHF 80.00
-2.5%
14.1%CHF 97.00CHF 65.00CHF 81.337
Aug ’24CHF 80.35
CHF 82.83
+3.1%
13.6%CHF 97.00CHF 65.00CHF 79.056
Jul ’24CHF 77.20
CHF 87.60
+13.5%
9.3%CHF 97.00CHF 74.00CHF 83.655
Jun ’24CHF 94.72
CHF 91.75
-3.1%
4.8%CHF 97.00CHF 86.00CHF 80.854
May ’24CHF 97.09
CHF 88.20
-9.2%
11.2%CHF 100.00CHF 71.00CHF 80.155
Apr ’24CHF 91.40
CHF 88.20
-3.5%
11.2%CHF 100.00CHF 71.00CHF 86.425
Mar ’24CHF 93.95
CHF 88.20
-6.1%
11.2%CHF 100.00CHF 71.00CHF 68.705
Feb ’24CHF 80.90
CHF 86.80
+7.3%
11.7%CHF 100.00CHF 71.00CHF 58.215
Jan ’24CHF 79.85
CHF 86.80
+8.7%
11.7%CHF 100.00CHF 71.00CHF 65.015
Dec ’23CHF 92.60
CHF 74.40
-19.7%
23.4%CHF 95.00CHF 48.00CHF 63.765
Nov ’23CHF 69.36
CHF 72.83
+5.0%
21.0%CHF 95.00CHF 48.00CHF 65.306

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£172.8m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

7D

-10.9%

1Y

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.35

7D

7.7%

1Y

-14.5%

Regeneron Pharmaceuticals

US$82.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$760.78

7D

-7.0%

1Y

-4.4%